The price-to-earnings ratio for Astrana Health Inc (NASDAQ: ASTH) is above average at 18.59x, Company’s 36-month beta value is 1.26.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ASTH is 36.62M, and currently, short sellers hold a 5.10% ratio of that floaft. The average trading volume of ASTH on February 28, 2025 was 319.34K shares.
ASTH) stock’s latest price update
Astrana Health Inc (NASDAQ: ASTH) has seen a decline in its stock price by -30.08 in relation to its previous close of 34.68. However, the company has experienced a -32.04% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-27 that Astrana Health, Inc. (NASDAQ:ASTH ) Q4 2024 Earnings Conference Call February 27, 2025 5:30 PM ET Company Participants Brandon Sim – President & CEO Chan Basho – Chief Operating & Financial Officer Conference Call Participants Ryan Daniels – William Blair Michael Ha – Baird Jailendra Singh – Truist Securities Ryan Langston – TD Cowen Adam Ron – Bank of America Craig Jones – Stifel Brooks O’Neil – Lake Street Capital David Larsen – BTIG Matt Gilmore – KeyBanc Capital Gene Mannheimer – Freedom Capital Markets Operator Good day, everyone, and welcome to today’s Astrana Health Fourth Quarter and Full Year 2024 Earnings Call. [Operator Instructions] Later, you will have the opportunity to ask questions during the question-and-answer session.
ASTH’s Market Performance
ASTH’s stock has fallen by -32.04% in the past week, with a monthly drop of -34.30% and a quarterly drop of -42.81%. The volatility ratio for the week is 4.78% while the volatility levels for the last 30 days are 4.09% for Astrana Health Inc The simple moving average for the last 20 days is -33.05% for ASTH stock, with a simple moving average of -45.42% for the last 200 days.
Analysts’ Opinion of ASTH
Many brokerage firms have already submitted their reports for ASTH stocks, with TD Cowen repeating the rating for ASTH by listing it as a “Buy.” The predicted price for ASTH in the upcoming period, according to TD Cowen is $66 based on the research report published on October 14, 2024 of the previous year 2024.
Truist gave a rating of “Buy” to ASTH, setting the target price at $50 in the report published on July 11th of the previous year.
ASTH Trading at -30.57% from the 50-Day Moving Average
After a stumble in the market that brought ASTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.63% of loss for the given period.
Volatility was left at 4.09%, however, over the last 30 days, the volatility rate increased by 4.78%, as shares sank -32.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.51% lower at present.
During the last 5 trading sessions, ASTH fell by -29.88%, which changed the moving average for the period of 200-days by -35.66% in comparison to the 20-day moving average, which settled at $36.26. In addition, Astrana Health Inc saw -23.09% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ASTH
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.14 for the gross margin
The net margin for Astrana Health Inc stands at 0.04. The total capital return value is set at 0.09. Equity return is now at value 6.50, with 3.73 for asset returns.
Based on Astrana Health Inc (ASTH), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is 2.78.
Currently, EBITDA for the company is 123.69 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of 0.78. The receivables turnover for the company is 7.62for trailing twelve months and the total asset turnover is 1.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In a nutshell, Astrana Health Inc (ASTH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
